Biotech | March 01, 2022
South Korea's OCI acquires 11% stake in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
Ind-Ra expects revenue growth of over 12% in 2022.
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The drug is also intended for the treatment of glioblastoma multiforme
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Subscribe To Our Newsletter & Stay Updated
